Novo Nordisk Plans To Initiate Phase 3a Development In Obesity With Oral Semaglutide

Novo Nordisk (NVO) said that it has decided to enter phase 3a development in obesity with oral semaglutide 50 mg.

The move comes following the completion of the STEP phase 3a clinical programme with once-weekly subcutaneous semaglutide 2.4 mg.

The company plans to initiate a pivotal phase 3a program with about 1,000 people with obesity or overweight with comorbidities.

The global 68-week trial is planned for initiation in the second half of 2021 and will investigate the efficacy and safety of oral semaglutide compared to placebo.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Pfizer and Moderna have raised the prices of their respective Covid vaccines for European Union, the Financial Times reported. Pharmaceutical giants renegotiated their covid vaccine supply contract with the EU citing global inflation, supply chain bottleneck and a high demand for the vaccines. A similar price hike is expected in other markets. Shares of HSBC Holdings Plc were gaining in London and Hong Kong trading after the Asia-focused lender reported Monday that its first-half profit more than doubled, despite weak revenues. Looking ahead, the company said while uncertainties remain, the outlook is more positive with evidence of growth in strategic areas. After Disney World, retail giant Walmart Inc. (WMT) makes it mandatory for all its employees to wear mask on their facilities in the "high-risk" states where the Delta variant of Coronavirus has become menacing. The orders will be in effect immediately. The Center for Disease Control and Prevention...
Follow RTT